Literature DB >> 24049113

Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats.

I Tong Mak1, Jay H Kramer, Xi Chen, Joanna J Chmielinska, Christopher F Spurney, William B Weglicki.   

Abstract

Use of protease inhibitors (PI) in HIV patients is associated with hyperlipidemia and increased risk of coronary heart disease. Chronic systemic and cardiac effects of ritonavir (RTV), a universal PI booster, and Mg supplementation were examined. RTV was administered (75 mg·kg(-1)·day(-1) po) to Lewis × Brown-Norway hybrid (LBNF1) rats for up to 8 wk; significant increases in plasma triglyceride and cholesterol occurred from 8 days to 8 wk. At 5 wk, the expression of selected hepatic genes (CYP7A1, CITED2, G6PC, and ME-1), which are key to lipid catabolism/synthesis, were altered toward lipogenesis. Dietary Mg supplementation (six-fold higher) completely reversed the altered expression of these genes and attenuated both hypertriglyceridemia and hypercholesterolemia. Neutrophils isolated from the RTV-treated rats displayed a three-fold higher basal and a twofold higher stimulated superoxide production; plasma isoprostane and red blood cell (RBC) GSSG levels were elevated two- to three-fold. All oxidative indices were normalized by Mg supplementation. After 5 wk, RTV caused significant decreases in cardiac left ventricular (LV) shortening fraction and LV ejection fraction; mitral valve early/late atrial ventricular filling (E/A) ratio was reduced accompanied by LV posterior wall thinning. Immunohistochemical staining revealed significant white blood cell (WBC) infiltration (5 wk) and prominent fibrosis (8 wk) in the RTV hearts. Mg supplementation attenuated RTV-induced declines in systolic and diastolic (improved mitral valve E/A ratio) function (>70%), lessened LV posterior wall thinning (by 75%), and substantially decreased the pathological markers. The known clinical hyperlipidemia effects of RTV can be mimicked in the LBNF1 rats; in association, systemic oxidative stress and progressive cardiac dysfunction occurred. Remarkably, Mg supplementation alone suppressed RTV-mediated hyperlipidemia, oxidative stress, and cardiac dysfunction.

Entities:  

Keywords:  HIV-1 protease inhibitor ritonavir; cardiac dysfunction; dietary Mg supplementation; hepatic metabolic gene regulation; hyperlipidemia; oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 24049113      PMCID: PMC3841797          DOI: 10.1152/ajpregu.00268.2013

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  44 in total

1.  Chronic disease self-management and adherence to HIV medications.

Authors:  Allen L Gifford; Erik J Groessl
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

Review 2.  HIV protease inhibitors and atherosclerosis.

Authors:  David Y Hui
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

3.  Quantification of renal pathology by image analysis.

Authors:  Gopala K Rangan; Greg H Tesch
Journal:  Nephrology (Carlton)       Date:  2007-12       Impact factor: 2.506

4.  Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade.

Authors:  I Tong Mak; Joanna J Chmielinska; Jay H Kramer; Christopher F Spurney; William B Weglicki
Journal:  Exp Clin Cardiol       Date:  2011

Review 5.  Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.

Authors:  Janice Yang Chou; Dietrich Matern; Brian C Mansfield; Yuan-Tsong Chen
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

Review 6.  Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia.

Authors:  Jay H Kramer; Christopher Spurney; Micaela Iantorno; Constantine Tziros; I-Tong Mak; M Isabel Tejero-Taldo; Joanna J Chmielinska; Andrei M Komarov; William B Weglicki
Journal:  Am J Med Sci       Date:  2009-07       Impact factor: 2.378

7.  HIV protease inhibitor ritonavir increases endothelial monolayer permeability.

Authors:  Changyi Chen; Xiang-Huai Lu; Shaoyu Yan; Hong Chai; Qizhi Yao
Journal:  Biochem Biophys Res Commun       Date:  2005-09-30       Impact factor: 3.575

Review 8.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Authors:  Robert K Zeldin; Richard A Petruschke
Journal:  J Antimicrob Chemother       Date:  2003-12-04       Impact factor: 5.790

9.  HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries.

Authors:  Brian S Conklin; Weiping Fu; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen
Journal:  Cardiovasc Res       Date:  2004-07-01       Impact factor: 10.787

Review 10.  Regulation of superoxide production in neutrophils: role of calcium influx.

Authors:  Sabrina Bréchard; Eric J Tschirhart
Journal:  J Leukoc Biol       Date:  2008-06-10       Impact factor: 4.962

View more
  17 in total

1.  Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.

Authors:  Joanna J Chmielinska; Jay H Kramer; I-Tong Mak; Christopher F Spurney; William B Weglicki
Journal:  Mol Cell Biochem       Date:  2019-12-18       Impact factor: 3.396

2.  EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.

Authors:  I Tong Mak; Jay H Kramer; Joanna J Chmielinska; Christopher F Spurney; William B Weglicki
Journal:  J Cardiovasc Pharmacol       Date:  2015-01       Impact factor: 3.105

Review 3.  Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease.

Authors:  Jasimuddin Ahamed; Hunter Terry; Mary E Choi; Jeffrey Laurence
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

4.  Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.

Authors:  Raza M Alvi; Anne M Neilan; Noor Tariq; Magid Awadalla; Maryam Afshar; Dahlia Banerji; Adam Rokicki; Connor Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-07-31       Impact factor: 24.094

5.  Relationship between the concentrations of heavy metals and bioelements in aging men with metabolic syndrome.

Authors:  Iwona Rotter; Danuta Kosik-Bogacka; Barbara Dołęgowska; Krzysztof Safranow; Anna Lubkowska; Maria Laszczyńska
Journal:  Int J Environ Res Public Health       Date:  2015-04-10       Impact factor: 3.390

6.  Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era.

Authors:  Fuu-Jen Tsai; Chi-Fung Cheng; Chih-Ho Lai; Yang-Chang Wu; Mao-Wang Ho; Jen-Hsien Wang; Ni Tien; Xiang Liu; Hsinyi Tsang; Ting-Hsu Lin; Chiu-Chu Liao; Shao-Mei Huang; Ju-Pi Li; Jung-Chun Lin; Chih-Chien Lin; Jin-Hua Chen; Wen-Miin Liang; Ying-Ju Lin
Journal:  Oncotarget       Date:  2017-11-15

7.  HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide.

Authors:  Jeffrey Laurence; Sonia Elhadad; Tyler Robison; Hunter Terry; Rohan Varshney; Sean Woolington; Shahrouz Ghafoory; Mary E Choi; Jasimuddin Ahamed
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

8.  Combination ART-Induced Oxidative/Nitrosative Stress, Neurogenic Inflammation and Cardiac Dysfunction in HIV-1 Transgenic (Tg) Rats: Protection by Mg.

Authors:  I Tong Mak; Joanna J Chmielinska; Christopher F Spurney; William B Weglicki; Jay H Kramer
Journal:  Int J Mol Sci       Date:  2018-08-15       Impact factor: 5.923

9.  Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system.

Authors:  Cagla Akay; Michael Cooper; Akinleye Odeleye; Brigid K Jensen; Michael G White; Fair Vassoler; Patrick J Gannon; Joseph Mankowski; Jamie L Dorsey; Alison M Buch; Stephanie A Cross; Denise R Cook; Michelle-Marie Peña; Emily S Andersen; Melpo Christofidou-Solomidou; Kathryn A Lindl; M Christine Zink; Janice Clements; R Christopher Pierce; Dennis L Kolson; Kelly L Jordan-Sciutto
Journal:  J Neurovirol       Date:  2014-01-14       Impact factor: 2.643

Review 10.  HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies.

Authors:  Jeffrey Laurence; Sonia Elhadad; Jasimuddin Ahamed
Journal:  Open Heart       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.